Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes

In this era of precision medicine, with the help of biomarkers, immunotherapy has significantly improved prognosis of many patients with malignant tumor. Deficient mismatch repair (dMMR)/microsatellite instability (MSI) status is used as a biomarker in clinical practice to predict favorable response...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wantao, Liu, Yihan, Zeng, Shan, Han, Ying, Shen, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499512/
https://www.ncbi.nlm.nih.gov/pubmed/34620200
http://dx.doi.org/10.1186/s13045-021-01166-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499512/
https://www.ncbi.nlm.nih.gov/pubmed/34620200
http://dx.doi.org/10.1186/s13045-021-01166-3

Ejemplares similares